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Abstract: Immune checkpoint inhibition is an effective anti-cancer therapeutic approach but has
shown limited efficacy in treating colorectal cancer (CRC) patients. Importantly, immune constituents
of the tumor microenvironment (TME) can influence therapy response and cancer progression. We
investigated the expression of immune checkpoints (ICs) on lymphoid populations within the CRC
TME and compared with cells from normal colon tissues using samples from 50 patients with varying
disease stages. We found that the levels of B cells, T cells, and NK cells were similar, IC-expressing
CD4+ and CD4+CD8+ double positive T cells were higher, while CD8+ T cells and CD4−CD8− double
negative T cells were significantly lower in CRC tumors. Notably, patients with mismatch-repair
deficiency/microsatellite instability-high tumors had higher levels of IC-expressing CD4+ and CD8+
T cells than patients with proficient MMR and microsatellite stable tumors. Lastly, The Cancer
Genome Atlas Colon Adenocarcinoma datasets showed associations between low expression of
selective genes and poorer progression-free interval. Our findings highlight differential expression of
ICs on lymphoid cells in CRC tumors in the era of cancer immunotherapy, which at present is solely
approved for anti-PD-1 therapy in patients with dMMR/MSI-H tumors. Further investigations into
their functionality have potentials for deciphering resistance mechanisms to IC inhibition.
Keywords: colorectal cancer; T cells; B cells; NK cells; immune checkpoints; dMMR; MSI-H; MSS
1. Introduction
Colorectal cancer (CRC) is the third most frequently diagnosed cancer amongst both
sexes, accounting for 9.2% global cancer-related mortality [1]. Promising anti-cancer
therapies such as immunotherapy have shown great advances in recent years but warrant
additional insights into interactions between tumor cells and tumor-infiltrating immune
cells (TIICs) to overcome resistance mechanisms and to improve response to therapy.
Immune constituents of the tumor microenvironment (TME) can influence disease
initiation, affect rate-limiting factors for disease progression and ultimately impact disease
prognosis [2]. Cells of myeloid and lymphoid lineage within the TME have both anti- and
pro-tumor roles, which may suppress tumor growth via production of pro-inflammatory
cytokines or direct tumor cell killing, or support tumor progression via angiogenesis
and invasion by favoring cell proliferation [3]. Correlations between immune infiltrates
and disease prognosis have been widely reported in different cancers including CRC [4].
Importantly, high levels of Th1/cytotoxic memory T cells in the tumor core and at the
invasive margin are associated with prolonged disease-free survival (DFS) and overall
survival (OS), accompanied with reduced threat of relapse and metastatic disease in CRC
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patients [5,6]. Therefore, lymphoid populations within the TME have cardinal roles in
tumor progression and in orchestrating response to therapy.
Immune checkpoints (ICs) have emerged as vital targets for eliciting potent anti-tumor
immune responses, primarily via inactivation of inhibitory immune receptors within the
TME [7]. Accumulating evidences have shown upregulation of ICs and their ligands within
the TME across different malignancies [8]. Studies have disclosed that IC pathways have
critical roles in the pathogenesis of CRC as evident from single nucleotide polymorphisms
of important IC genes in CRC patients [9], accumulation of IC-expressing immune cells in
the TME [10] and associations with TIL load, rate of mutations, and survival [11]. Therefore,
blocking IC pathways for therapeutic benefits has been comprehensively explored in
treating CRC patients.
Studies have shown that CRC patients presenting with mismatch-repair deficiency
(dMMR) and microsatellite instability-high (MSI-H) tumors exhibit sustained and durable
clinical responses to IC blockade, compared to patients with proficient MMR [12]. Loss of
MMR proteins provide phenotypic evidence of MSI-H tumors with dMMR, whereas MMR-
proficient tumors comprise MSI-low or microsatellite stable (MSS) tumors with unmarked
MMR proteins [13]. However, the favorable effects of MSI-H tumors on successful IC
inhibition are often decreased in advanced stages or in metastatic CRC [14]. Moreover, overall
response rates among all CRC patients treated with IC inhibition remain low, primarily due to
tumor intrinsic/extrinsic mechanisms of resistance or recurrent accounts of immune-related
adverse events (irAEs) [15,16]. In addition, evolving ICs such as T cell immunoglobulin
and mucin domain-containing protein 3 (TIM-3), lymphocyte activation gene 3 (LAG-3), T
cell immunoreceptor with Ig and ITIM domains (TIGIT) and inducible T cell costimulatory
(ICOS) among others, are relatively in adolescent phase in their clinical translation as part
of cancer immunotherapy regimens, compared to established ICs; programmed cell death
protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
In this study, we performed critical immune cell profiling of colorectal tumors by
focusing on lymphoid cell populations within the TME and investigated expression levels
of ICs in a CRC cohort comprising of patients with varying disease stages. We investigated
the levels of tumor-infiltrating B cells, T cells and NK cells compared to normal tissue
milieu and established the expression profiles of PD-1, TIM-3, LAG-3, TIGIT, and ICOS
on the different tumor-resident lymphoid populations. We also investigated associations
between the levels of different IC-expressing lymphoid cells in the TME and disease stage to
decipher their plausible roles in tumor progression. Importantly, we identified patients with
MSI-H and MSS from our cohort and compared the levels of tumor-infiltrating lymphoid
cells and IC expression between them. Lastly, we explored the clinical importance of our
findings by investigating gene expression levels of the selected markers that have been
elevated in CRC tumors with patient survival data from The Cancer Genome Atlas Colon
Adenocarcinoma (TCGA-COAD) datasets.
At present, only anti-PD-1 is approved for treating CRC patients with unresectable
or metastatic dMMR/MSI-H tumors, and only recently approved as a first-line treatment
in these patients, based on KEYNOTE-177 study [17,18]. Other IC pathways are currently
being explored for therapeutic benefits in CRC patients. Therefore, our main focus was
to provide insights into the expression levels of different IC molecules in CRC tumors,
while highlighting the significance of dMMR/MSI-H tumors. Our data highlight the role of
different lymphoid cells within CRC TME and uncover the expression levels of emerging
ICs on different populations within the TME, which is supported with patient survival data
from TCGA datasets, to provide credible targets for successful IC inhibition for improving
clinical outcomes in CRC patients.
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2. Materials and Methods
2.1. Sample Acquisition and Storage
This study was approved by the Institutional Review Boards at Qatar Biomedical
Research Institute (QBRI) (Study no. 2018-018) and Hamad Medical Corporation (HMC)
(Study no. MRC-02-18-012), Doha, Qatar.
Tumor tissues (TT) and corresponding, non-tumor normal tissues (NT), identified by a
pathologist, were obtained from treatment-naïve CRC patients (n = 50) who undertook surgical
resection at HMC. Informed consents were obtained from all patients before sample collection.
The pathological and clinical characteristics of the study cohort are listed in Table 1.
Table 1. Clinical and pathological features of study cohort.
CRC Patients
Number 50








G2 (Moderately differentiated) 45
G3 (Poorly differentiated) 5
dMMR/MSI-H 8
CRC; colorectal cancer; dMMR/MSI-H; Mismatch-repair deficiency/Microsatellite instability-high; † Median age.
Bold represents main text/subheading.
Tissue specimens were stored in freezing media (10% DMSO, 40% RPMI 1640 media
and 50% fetal bovine serum) and used in batches for analyses.
2.2. Cell Segregation from Colorectal Tumor Tissues and Normal Colon Tissues
Cells from NT and TT were isolated by mechanical disaggregation, as previously
described [10]. Frozen tissues were thawed, washed twice with phosphate-buffered saline
(PBS) and mechanically cut into small sections (~2–4 mm). Tissue disaggregation was
performed by using gentleMACSTM Dissociator (Miltenyi Biotech, Bergisch Gladbach,
Germany) in the absence of proteolytic enzymes. A cell strainer (100 µM) was used to
eliminate cell aggregates and debris. The cell suspension was washed with PBS and stained
with different antibodies for multi-parametric flow cytometric analyses.
2.3. Flow Cytometric Analyses
Cells were re-suspended in 100 µL flow cytometry staining buffer (0.1% sodium azide
and 1% FCS in PBS; FACS buffer). FcR Blocking reagent (Miltenyi Biotech) was added
for blocking Fc receptors. 7-Aminoactinomycin D (7-AAD) Viability Staining Solution
(BioLegend, San Diego, CA, USA) was added to gate live cells. Cell surface antibod-
ies against CD3-BrilliantTM Ultraviolet 496 (BUV496; clone UCHT-1; BD Biosciences,
Oxford, UK), CD4-Fluorescein Isothiocyanate (FITC; clone RPA-T4; BD Biosciences), CD8-
Phycoerythrin Cyanine 7 (PE/Cy7; clone RPA-T8; BioLegend, San Diego, CA, USA), CD19-
Allophycocyanin Cyanine 7 (APC-Cy7; clone HIB19; eBioscience, San Diego, CA, USA),
CD56-Phycoerythrin (PE; clone B159; BD Biosciences), PD-1-PE/DazzleTM 594 (clone
EH12.2H7; BioLegend), TIM-3-Brilliant Violet 711 (BV711; clone 7D3; BD Biosciences),
LAG-3-Brilliant violet 421 (clone T47-530; BD Biosciences), TIGIT-APC (clone MBSA43;
eBioscience) and ICOS-Alexa Fluor 700 (AF700; clone C398.4A; BioLegend) were added,
and cells were incubated for 30 min at 4 ◦C. Cells were washed twice and resuspended
in FACS buffer. Fluorescence minus one (FMO) control(s) and isotype-matched control(s)
were used for data interpretation and validation of antibody staining for phenotypical anal-
yses. Data acquisition was performed on a BD LSRFortessa X-20 flow cytometer running
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on BD FACSDiva software (BD Biosciences), and the generated data were analyzed on
FlowJo V10 software (FlowJo, Ashland, OR, USA).
2.4. Analyses Using the Cancer Genome Atlas (TCGA) Colorectal Cancer
Certain genes, based on the protein expression on immune cell infiltrates from our
findings, were selected to extract RNA Seq data for these genes for analyses in TCGA CRC
dataset. The survival and phenotype data were obtained from TCGA database to plot
Kaplan–Meier survival curves and calculate log-rank p values using Graphpad Prism 8.
Chi-squared χ2 test was used to check he statistical significance of the distribution of CRC
patients across different disease stages.
2.5. Statistical Analyses
Statistical analyses were performed on GraphPad Prism 8 software (GraphPad Soft-
ware, San Diego, CA, USA). In grouped analyses, One-way Anova test was used to investi-
gate statistical significance. Paired t-tests/Wilcoxon matched-pairs signed rank tests were
implemented within groups and Unpaired t-tests/Mann–Whitney between groups, based
on Shapiro–Wilk normality test to establish data distribution. In all analyses, a p value of
<0.05 was considered statistically significant and represented as: *; p < 0.05, **; p < 0.01 and
***; p < 0.001. Presented data show mean ± standard error of the mean (SEM).
3. Results
3.1. Tumor-Infiltrating Immune Cells in Colorectal Tumors
We performed phenotypical characterization of TIICs and compared with immune
cells in normal colon tissues of CRC patients (n = 50). We focused on lymphoid cells due
to their cardinal roles in anti-tumor immune responses. We found that B cells and T cells
are abundantly present in normal colon milieu and in the CRC TME, compared to NK
cells (Figure 1A). Importantly, we found that levels of these cells were similar in NT and
TT, although B cells showed a trend towards reduced levels in the TME, but the data did
not reach statistical significance. NK cells also showed a statistically insignificant, trend
towards lower levels in the TME compared to normal tissue.




Figure 1. Lymphocyte populations in the colorectal tumor microenvironment. Levels of lymphoid cells were measured in 
the tumor microenvironment of colorectal cancer (CRC) patients, compared with their levels in normal tissues. Cells were 
isolated from tumor tissues (TT) and normal tissues (NT) of 50 CRC patients for flow cytometric analyses. CRC patients 
for flow cytometric analyses. Representative flow cytometric plots and cumulative scatter plots show levels of CD19+ B 
cells, CD3+ T cells and CD56+ NK cells in NT and TT (A). Representative flow cytometric plots and cumulative scatter plots 
show levels of different CD3+ T cell subsets; CD4+, CD8+, CD4−CD8−(DN), and CD4+CD8+ (DP) T cells in NT and TT (B). 
The p values are represented as follows; * p < 0.05, ** p < 0.01, *** p < 0.001. 
3.2. Immune Checkpoint Expression on Lymphoid Cell Populations in CRC TME 
PD-1, TIM-3, LAG-3, TIGIT, and ICOS are identified as important co-inhibitory/stim-
ulatory receptors expressed on immune cells [19]. While expression of these receptors is 
almost exclusively studied on T cells, their expression levels on other lymphoid cells in 
the CRC TME remain to be elucidated. Therefore, we investigated expression of these re-
ceptors on TIICs from colorectal tumors and compared their expression on cells isolated 
from colon NT (Figure 2). We found that co-inhibitory molecules PD-1, TIM-3, LAG-3, 
and TIGIT were expressed on relatively low levels on B cells in NT and TT with some 
evidence of upregulation on B cells isolated from TT (Figure 2A). In contrast, co-stimula-
tory receptor ICOS on B cells was expressed at significantly higher levels in TT, compared 
with NT (NT; 3.4 ± 0.7 vs. TT; 27.1 ± 4.7, Figure 2A). 
Tumor-infiltrating CD4+ T cells showed significantly elevated expression of PD-1 
(NT; 32.5 ± 2.0 vs. TT; 46.3 ± 2.7), TIM-3 (NT; 2.7 ± 0.3 vs. TT; 10.8 ± 1.3) and TIGIT (NT; 
26.5 ± 1.8 vs. TT; 37.0 ± 2.1), but not LAG-3 (Figure 2B). Interestingly, ICOS was also sig-
nificantly overexpressed on CD4+ TILs than NILs (NT; 21.0 ± 1.5 vs. TT; 40.0 ± 2.6). CD8+ 
TILs also showed a similar pattern of IC expression as CD4+ TILs in CRC TME; PD-1 (NT; 
3.5 ± 1.0 vs. TT; 22.0 ± 3.1), TIM-3 (NT; 3.7 ± 0.6 vs. TT; 18.9 ± 2.6), TIGIT (NT; 22.1 ± 1.6 vs. 
TT; 27.3 ± 2.6) and ICOS (NT; 3.7 ± 0.3 vs. TT; 14.9 ± 2.0) were significantly overexpressed 
on CD8+ TILs compared to cells isolated from NT (Figure 2C). 
Next, we investigated IC expression on NK cells from NT and TT of CRC patients. 
Crucially, we found that of all the ICs investigated, only TIM-3 was expressed at signifi-
cantly higher levels on NK cells in TT compared to NT (NT; 7.3 ± 1.1 vs. TT; 18.7 ± 2.4, 
Figure 2D). 
Figure 1. Lymphocyte populations in the colorectal tumor microenvir t. Levels of lymphoid cells wer measured in
the tumor microenvironment of colorectal cancer (CRC) patients, co pared ith their levels in normal tissues. Cells were
isolated from tumor tissues (TT) and normal tissues (NT) of 50 CRC patients for flow cytometric analyses. CRC patients for
flow cytometric analyses. Representative flow cytometric plots and cumulative scatter plots show levels of CD19+ B cells,
CD3+ T cells and CD56+ NK cells in NT and TT (A). Representative flow cytometric plots and cumulative scatter plots show
levels of different CD3+ T cell subsets; CD4+, CD8+, CD4−CD8−(DN), and CD4+CD8+ (DP) T cells in NT and TT (B). The p
values are represented as follows; * p < 0.05, ** p < 0.01, *** p < 0.001.
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Next, we focused our investigations on the phenotypical characterization of T cells in
normal tissue-infiltrating lymphocytes (NILs) and tumor-infiltrating lymphocytes (TILs)
(Figure 1B). We investigated levels of four main subtypes of T cells; CD4+, CD8+, double
negative (CD4−CD8−; DN) and double positive (CD4+CD8+; DP) T cells, and found that
the majority of T cells in NT and TT comprised of CD4+ or CD8+ T cells, followed by DN T
cells while DP T cells were present at lower levels. Importantly, we found that CD4+ T cells
and DP T cells were present at significantly higher levels in TT compared to NT (CD4+:
NT; 23.7 ± 2.0 vs. TT; 36.3 ± 2.2, DP: NT; 0.3 ± 0.1 vs. TT; 0.6 ± 0.1), while CD8+ T cells
and DN T cells were present at significantly lower levels in TT compared to NT (CD8+: NT;
57.6 ± 2.1 vs. TT; 52.4 ± 2.2, DN: NT; 14.0 ± 1.6 vs. TT; 6.8 ± 1.0) (Figure 1B).
3.2. Immune Checkpoint Expression on Lymphoid Cell Populations in CRC TME
PD-1, TIM-3, LAG-3, TIGIT, and ICOS are identified as important co-inhibitory/
stimulatory receptors expressed on immune cells [19]. While expression of these receptors
is almost exclusively studied on T cells, their expression levels on other lymphoid cells
in the CRC TME remain to be elucidated. Therefore, we investigated expression of these
receptors on TIICs from colorectal tumors and compared their expression on cells isolated
from colon NT (Figure 2). We found that co-inhibitory molecules PD-1, TIM-3, LAG-3, and
TIGIT were expressed on relatively low levels on B cells in NT and TT with some evidence
of upregulation on B cells isolated from TT (Figure 2A). In contrast, co-stimulatory receptor
ICOS on B cells was expressed at significantly higher levels in TT, compared with NT (NT;
3.4 ± 0.7 vs. TT; 27.1 ± 4.7, Figure 2A).




Figure 2. Immune checkpoint expression on different lymphocyte populations in the colorectal 
tumor microenvironment. We investigated differences in levels of immune checkpoints; PD-1, 
TIM-3, LAG-3, TIGIT, and ICOS-expressing B cells, CD4+ T cells, CD8+ T cells and NK cells in NT 
and TT of 50 CRC patients. Cumulative scatter plots show differences in levels of IC-expressing B 
cells (A), CD4+ T cells (B), CD8+ T cells (C), and NK cells (D) in NT and TT. The p values are repre-
sented as follows; * p < 0.05, *** p < 0.001. 
3.3. Immune Checkpoint Co-Expression on T Cells in the CRC TME 
Recent studies have shown that multiple ICs can be expressed on TILs and have im-
portant implications on their roles in tumor progression. For instance, Yang et al., have 
recently shown that TIGIT+PD-1+ T cells are functionally exhausted with impaired ability 
to induce anti-tumor immune responses [20]. Similarly, PD-1+TIM-3+ TILs exhibit the most 
severe exhausted phenotype in the TME [21]. In addition, Di Blasi et al., showed that ac-
cumulation of ICOS and TIGIT co-expressing TILs in hepatocellular carcinoma, which 
were functionally impaired [22]. Therefore, we investigated the levels of ICOS+TIGIT+ 
and PD-1+TIM-3+ TILs in CRC tumors compared to NT (Figure 3). We found that both 
CD4+ICOS+TIGIT+ (NT; 13.9 ± 1.3 vs. TT; 23.6 ± 1.7) and CD8+ICOS+TIGIT+ (NT; 1.4 ± 0.2 
vs. TT; 5.8 ± 1.1) cells were present at significantly higher levels in TT compared to NT 
(Figure 3A). Likewise, we found that CD4+PD-1+TIM-3+ (NT; 1.8 ± 0.2 vs. TT; 8.7 ± 1.1) and 
CD8+PD-1+TIM-3+ (NT; 0.2 ± 0.1 vs. TT; 10.4 ± 1.9) cells were also present at significantly 
higher levels in TT compared to NT (Figure 3B). 
Figure 2. I mune checkpoint expression on different lymphocyte populatio s in the colorectal
tumor microenviron e t. f re ces in levels of immune checkpoints; PD-1, TIM-3,
LAG-3, TIGIT, and ICOS-expressing B cells, CD4+ T cells, CD8+ T cells and NK cells in NT and
TT of 50 CRC patients. Cumulative scatter plots show differences in levels of IC-expressing B cells
(A), CD4+ T cells (B), CD8+ T cells (C), and NK cells (D) in NT and TT. The p values are represented
as follows; * p < 0.05, *** p < 0.001.
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Tumor-infiltrating CD4+ T cells showed significantly elevated expression of PD-1 (NT;
32.5 ± 2.0 vs. TT; 46.3 ± 2.7), TIM-3 (NT; 2.7 ± 0.3 vs. TT; 10.8 ± 1.3) and TIGIT (NT;
26.5 ± 1.8 vs. TT; 37.0 ± 2.1), but not LAG-3 (Figure 2B). Interestingly, ICOS was also
significantly overexpressed on CD4+ TILs than NILs (NT; 21.0 ± 1.5 vs. TT; 40.0 ± 2.6).
CD8+ TILs also showed a similar pattern of IC expression as CD4+ TILs in CRC TME; PD-1
(NT; 3.5 ± 1.0 vs. TT; 22.0 ± 3.1), TIM-3 (NT; 3.7 ± 0.6 vs. TT; 18.9 ± 2.6), TIGIT (NT;
22.1 ± 1.6 vs. TT; 27.3 ± 2.6) and ICOS (NT; 3.7 ± 0.3 vs. TT; 14.9 ± 2.0) were significantly
overexpressed on CD8+ TILs compared to cells isolated from NT (Figure 2C).
Next, we investigated IC expression on NK cells from NT and TT of CRC patients.
Crucially, we found that of all the ICs investigated, only TIM-3 was expressed at signifi-
cantly higher levels on NK cells in TT compared to NT (NT; 7.3 ± 1.1 vs. TT; 18.7 ± 2.4,
Figure 2D).
3.3. Immune Checkpoint Co-Expression on T Cells in the CRC TME
Recent studies have shown that multiple ICs can be expressed on TILs and have
important implications on their roles in tumor progression. For instance, Yang et al.,
have recently shown that TIGIT+PD-1+ T cells are functionally exhausted with impaired
ability to induce anti-tumor immune responses [20]. Similarly, PD-1+TIM-3+ TILs ex-
hibit the most severe exhausted phenotype in the TME [21]. In addition, Di Blasi et al.,
showed that accumulation of ICOS and TIGIT co-expressing TILs in hepatocellular car-
cinoma, which were functionally impaired [22]. Therefore, we investigated the levels of
ICOS+TIGIT+ and PD-1+TIM-3+ TILs in CRC tumors compared to NT (Figure 3). We found
that both CD4+ICOS+TIGIT+ (NT; 13.9 ± 1.3 vs. TT; 23.6 ± 1.7) and CD8+ICOS+TIGIT+ (NT;
1.4 ± 0.2 vs. TT; 5.8 ± 1.1) cells were present at significantly higher levels in TT com-
pared to NT (Figure 3A). Likewise, we found that CD4+PD-1+TIM-3+ (NT; 1.8 ± 0.2 vs. TT;
8.7 ± 1.1) and CD8+PD-1+TIM-3+ (NT; 0.2 ± 0.1 vs. TT; 10.4 ± 1.9) cells were also present at
significantly higher levels in TT compared to NT (Figure 3B).




Figure 3. Immune checkpoint co-expression on different T cell subsets in the colorectal tumor mi-
croenvironment. We investigated co-expression of TIGIT/ICOS and PD-1/TIM-3 on CD4+ T cells, 
CD8+ T cells in TT and NT of 50 CRC patients. Representative flow cytometric plots and cumula-
tive scatter plots show differences in levels of ICOS−/+TIGIT−/+ (A) and PD-1−/+TIM-3−/+ (B) on CD4+ 
and CD8+ T cells in NT and TT. The p values are represented as follows; *** p < 0.001. 
3.4. Tumor-Infiltrating Immune Cells in Advanced and Early Stage CRC Patients 
To elucidate the plausible roles of various IC-expressing lymphoid cells in the TME 
with the progression of CRC, we compared the levels of different IC-expressing cellular 
populations between patients with advanced (III and IV, n = 25) and early (I and II, n = 25) 
stages. First, we investigated differences in levels of B cells, T cells and NK cells between 
patients with advanced and early stage CRC. We found that levels of tumor-infiltrating B 
cells were present at significantly lower levels in patients with advanced stage disease (A; 
18.1 ± 2.6 vs. E; 26.6 ± 4.0, Figure 4A). However, other cellular populations including dif-
ferent T cell subsets did not show any statistically significant differences (data not shown). 
Next, we compared the levels of tumor-infiltrating B cells, T cells and their subsets, 
and NK cells expressing PD-1, TIM-3, LAG-3, TIGIT, and ICOS between patients with 
advanced and early stage CRC. Interestingly, we found significantly lower levels of PD-1 
in advanced stage CRC (A;16.2 ± 3.0 vs. E; 26.0 ± 3.6), TIM-3 (A; 12.6 ± 2.4 vs. E; 20.3 ± 3.0) 
and TIGIT (A; 23.9 ± 2.6 vs. E; 31.2 ± 3.0)-expressing CD8+ T cells in the TME compared to 
CRC patients with early stage disease. Moreover, CD8+ICOS+ TILs also showed a trend of 
reduction in patients with advanced stage disease, but the data did not reach statistical 
significance. Other IC-expressing cellular populations did not show any differences be-
tween patients with advanced and early stage CRC (data not shown). 
Figure 3. Immune checkpoint co-expression on different T cell subsets in the colorectal tumor
microenvironment. We investigated co-expression of TIGIT/ICOS and PD-1/TIM-3 on CD4+ T cells,
CD8+ T cells in T and NT of 50 CRC patients. Representative flo cyto etric l ts tive
scatter plots show differences in leve s of ICOS−/+TIG T−/+ (A) and PD-1− TIM-3−/+ (B) on CD4+
and CD8+ T cells in NT and TT. The p values are represented as follows; *** p < 0.001.
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3.4. Tumor-Infiltrating Immune Cells in Advanced and Early Stage CRC Patients
To elucidate the plausible roles of various IC-expressing lymphoid cells in the TME
with the progression of CRC, we compared the levels of different IC-expressing cellular
populations between patients with advanced (III and IV, n = 25) and early (I and II, n = 25)
stages. First, we investigated differences in levels of B cells, T cells and NK cells between
patients with advanced and early stage CRC. We found that levels of tumor-infiltrating B
cells were present at significantly lower levels in patients with advanced stage disease (A;
18.1 ± 2.6 vs. E; 26.6 ± 4.0, Figure 4A). However, other cellular populations including
different T cell subsets did not show any statistically significant differences (data not shown).
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Next, we compared the levels of tumor-infiltrating B cells, T cells and their subsets,
and NK cells expressing PD-1, TIM-3, LAG-3, TIGIT, and ICOS between patients with
advanced and early stage CRC. Interestingly, we found significantly lower levels of PD-
1 in advanced stage CRC (A;16.2 ± 3.0 vs. E; 26.0 ± 3.6), TIM-3 (A; 12.6 ± 2.4 vs. E;
20.3 ± 3.0) and TIGIT (A; 23.9 ± 2.6 vs. E; 31.2 ± 3.0)-expressing CD8+ T cells in the
TME compared to CRC patients with early stage disease. Moreover, CD8+ICOS+ TILs also
showed a trend of reduction in patients with advanced stage disease, but the data did not
reach statistical significance. Other IC-expressing cellular populations did not show any
differences between patients with advanced and early stage CRC (data not shown).
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3.5. CRC Patients with dMMR/MSI-H Tumors Have Higher Levels of CD8+ TILs and Exhibit
Elevated Expression of Immune Checkpoints
Eight patients out of our total patient cohort (n = 50) exhibited MSI-H, as con-
firmed by pathological assessment of TT (loss of expression of MMR proteins; MLH1,
MSH2, MSH6 and PMS2 by immunohistochemistry). We compared the levels of different
tumor-infiltrating lymphoid cells and IC expression, between patients exhibiting MSI-H
versus MMR proficient/MSS tumors (Figure 4B). We found that patients with MSI-H
tumors had significantly lower levels of CD4+ TILs compared to MSS tumors (MSI-H;
26.8 ± 3.4 vs. MSS; 40.2 ± 2.1). Moreover, CD4+ TILs from patients with MSI-H tumors
showed significantly higher expression of TIM-3 (MSI-H; 17.7 ± 2.1 vs. MSS; 9.2 ± 1.2),
TIGIT (MSI-H; 47.3 ± 3.3 vs. MSS; 34.8 ± 1.9), and co-expression of PD-1/TIM-3 (MSI-H;
15.1 ± 2.1 vs. MSS; 7.3 ± 1.1) and ICOS/TIGIT (MSI-H; 32.0 ± 3.7 vs. MSS; 21.8 ± 1.5),
compared to MSS tumors. In contrast, MSI-H tumors showed significantly higher levels
of CD8+ TILs (MSI-H; 64.3 ± 4.0 vs. MSS; 47.7 ± 2.1), which expressed TIM-3 (MSI-H;
33.0 ± 5.2 vs. MSS; 15.4 ± 2.2) at significantly higher levels than MSS tumors. In addition,
PD-1 and TIM-3 co-expressing DN T cells were also present at significantly higher levels
in MSI-H tumors compared to MSS tumors (MSI-H; 16.6 ± 6.8 vs. MSS; 2.5 ± 0.7). Of
note, we did not find any statistically significant differences between levels of overall and
IC-expressing B cell, CD3+ T cell and NK cell populations (data not shown).
3.6. TCGA Datasets Showed Higher Expression of Lymphoid-Related and IC Genes in Early Stages
of CRC
Our data showed similar levels of B cells, T cells and NK cells in the CRC TME
compared to NT, but these lymphoid cell populations show elevated expression of selective
ICs in the TME. Importantly, we found that patients with advanced stage disease have
lower levels of tumor-infiltrating B cells and IC-expressing CD8+ T cells. To find out
the plausible clinical significance of these results, we investigated associations between
elevated expression levels of CD3E, CD4, CD8A, CD19, NCAM1 (gene for CD56), PDCD1
(gene for PD-1), HAVCR2 (gene for TIM-3), LAG3, TIGIT, and ICOS genes with clinical
parameters including disease-specific survival (DSS), overall survival (OS), and progression-
free interval (PFI) from TCGA datasets of CRC patients (Figure 5). We divided patients
into two groups based on median expression levels of these genes, low expression and
high expression, and investigated associations between individual gene expression and
patient survival. We did not find any significant association between elevated expression of
these genes with OS and DSS (data not shown). Survival analyses using Kaplan–Meier and
log-rank test showed that low expression levels of genes including CD3E (p = 0.031), CD8A
(p = 0.014), TIGIT (p = 0.020), and ICOS (p = 0.002) were significantly associated with poorer
PFI (Figure 5A). Next, we investigated associations between combined elevated expression
levels of CD3E, CD4, CD8A, CD19, NCAM1, PDCD1, HAVCR2, LAG3, TIGIT, and ICOS
genes with disease staging (Figure 5B). We found that patients with advanced stages (stages
III and IV) showed decreased expression levels of these genes compared to patients with
early stage disease (stages I and II) (χ2 p = 0.045, Figure 5B). Taken together, the TCGA
analyses showed that advanced stage CRC patients have reduced levels of lymphoid and
IC genes but importantly, lower expression levels of CD3E, CD8A, TIGIT, and ICOS were
associated with poorer PFI.
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4. Discussion
TIICs are vital indicators of anti-tumor immune responses and can ultimately affect
disease prognosis in multiple cancers including CRC [23]. Conclusive evidence showed that
Th-1-polarized CD8+ T cells and presence of CD45RO+ memory T cells can influence tumor
progression and metastasis [5,24]. Thus, introduction of “immunoscore” based on the levels
of CD3+ and CD45RO+, CD3+ and CD8+, or CD8+ and CD45RO+ in the core tumor (CT)
and at the invasive margin (IM) by Galon et al., showed superior prognostic ability in CRC
patients [25]. Moreover, within the TME, different immune cell populations perform their
specialized functions such as NK cells involved in lysis of tumor cells, which lose MHC
class I expression [26], and B cells, which can modulate immune responses via various
mechanisms, including inhibition of T cell responses [27]. Importantly, ICs have emerged
as important molecules, which can affect the functionality of immune cells, as evident by
activation/hyperactivity of T cells or T cell exhaustion exhibited by IC-expressing T cells.
Shimabukuro-Vornhagen et al., have previously shown elevated levels of tumor-
infiltrating B cells compared to circulation in CRC patients [28]. Importantly, the authors
showed that these tumor-infiltrating B cells were highly activated and showed elevated
levels of memory B cells in the TME and in circulation of CRC patients compared with
circulation of healthy donors [28]. However, the authors did not compare the levels with
tissue resident B cells in normal colon tissue. Our data showed that the levels of overall B
cells were similar between tumor and normal tissue, but express significantly higher levels
of co-stimulatory IC, ICOS in the TME. These data show that B cells within the TME may
support T cell activation. Of note, an important subset of B cells recognized as B regulatory
cells (Bregs) has emerged as a potent immunosuppressive cell type, which can attenuate
anti-tumor immune responses [27]. Further investigations are warranted to identify the
levels of Bregs within CRC TME to disclose the balance between different T cell stimulating
or inhibiting B cell subsets within the CRC TME.
Vaccines 2021, 9, 64 10 of 14
Elevated T cell infiltration in CRC tumors is concomitant with improved survival [29].
Sherwood et al., reported that TCR repertoire analyses of T cells in CRC TME compared to
normal tissues showed wider diversity than variation of T-cell clones in healthy mucosa [30].
Our data provide important insights into the distribution of T cells within the TME; subsets
of CD4+ T cells and DP T cells have been shown to have immunosuppressive roles in
CRC [31–33], while DN T cells may also exhibit immunoregulatory potential [34] but
CD8+ T cells within TME show potent anti-tumor activity evident from granzyme B
expression [35]. In addition, infiltration of NK cells alongside CD8+ T cells in the TME,
has been shown to be associated with improved prognosis in CRC patients [36]. Ndhlovu
et al., reported that NK-cell responses are negatively regulated by interactions of TIM-3-
expressing NK cells with cognate ligands of TIM-3 [37]. Overall, the balance of the different
T cell subsets in favor of lower levels of CD8+ T cells compared to CD4+ T cells, and TIM-3+
NK cells, which can further dampen T cell responses within CRC TME, highlighting an
immune tolerant environment to aid tumor progression.
Immune checkpoints on T cells influence response to TCR ligation by cognate antigen
and can affect downstream signaling pathways for their activation, survival, and func-
tion [38]. Importantly, ICs are also over-expressed on exhausted T cells, characterized by
their inability to produce effector cytokines [39]. PD-1, TIM-3, and TIGIT are negative
regulators of T cell activation, which suppress their activation, proliferation and cytokine
production upon interactions with their ligands [19]. In contrast, ICOS serves as a co-
stimulatory molecule with opposing effects on T cell activation, proliferation and function-
ality [19]. The prognostic significance of ICs in CRC has been explored previously [11,40].
We identified that only CD8+ T cells expressing different ICs were found at lower levels in
CRC patients with advanced stage disease. Furthermore, we showed that some of these
ICs are co-expressed on tumor-infiltrating T cell subsets in CRC patients. Co-expression of
multiple ICs can have important implications on resistance mechanisms to immunotherapy
by unique or overlapping IC pathways, which may assist tumor progression [41,42].
Chromosomal instability is identified as a prerequisite for the development of majority
of CRC and around 12–15% of all CRC tumors exhibit dMMR, which is characterized
by MSI [13]. MSI-H CRC tumors have been previously reported to have high immune
cell infiltration, which include CD8+, Th1 TILs, and macrophages [43,44]. Moreover,
associations between elevated levels of tumor-infiltrating T cells and MSI-H in CRC patients
have also been reported [45]. These evidences suggest that CRC patients with MSI-H could
respond better to immunotherapy treatments and also have better disease prognosis.
However, disease prognosis remains worse in majority of CRC patients with advanced
stage disease, devoid of MMR status, implying the presence of other mechanisms driving
tumor progression or hampering response to therapy in such patients. Importantly, Llosa
et al., reported that MSI-H tumors could potentially offset the Th1/CTL balance in the CRC
TME by upregulation of multiple ICs [46].
To translate the clinical relevance of our findings, we investigated associations be-
tween protein expression of genes under scrutiny in our study with patient survival data
from TCGA datasets. We found that high expression of genes related to CD3+ and CD8+ T
cells, TIGIT and ICOS showed an association with a longer PFI. Moreover, patients with
advanced stage disease showed lower levels of these genes. These finding are in agreement
with our data that CRC patients with advanced stage disease showed lower levels of
IC-expressing CD8+ T cells in the TME. In contrast, it has been reported that the elevated
mRNA expression levels of CTLA-4, TIM-3, TIGIT, and VISTA among others were elevated
in the TME of CRC patients with advanced stage disease, compared with early stages [40].
Kitsou et al., have recently reported associations between elevated PD-1 and TIGIT gene
expression with better overall survival, and reported associations between TIL load and
HAVCR2, LAG-3 and TIGIT in CRC patients [11]. Chen et al. also reported elevated expres-
sion of PD-L1, TIL load and mutation burden in low-risk CRC patients [47]. Importantly,
the consensus molecular subtypes (CMS) classified CRC subtypes into four groups based
on genetic modifications and tumor immune profiling; CMS1 (MSI-H, immune activated),
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CMS2 (activated WNT and MYC signaling), CMS3 (dysregulation of metabolic pathways)
and CMS4 (immune inflamed, TGF-β activation) [48]. While, CMS1 tumors exhibit potent
anti-tumor activity, transcription of genes encoding ICs such as PDCD1, CD274, CTLA4,
and LAG3 may aid tumor immune escape in these tumors [49].
5. Conclusions
Previously reported findings from gene expression, combined with our data of protein
expression of different IC genes on various immune cells present in the TME of CRC
patients provide important insights in the timely field of cancer immunotherapy. We found
that multiple ICs are differentially upregulated/co-expressed on various immune cells
in the TME and decreased levels of B cells and selective IC-expressing CD8+ TILs are
associated with tumor progression. Importantly MSI-H tumors could show favorable
prognosis/improved response to cancer immunotherapy due to elevated levels of CD8+
TILs and elevated levels of IC-expressing CD4+ TILs compared to MSS tumors. These data
show that IC pathways can have significant implications on the prognosis and therapy
response in CRC patients and highlight important IC molecules, in addition to PD-1, which
may be targeted for therapeutic benefits. Figure 6 provides an overview of the presence
of multiple lymphoid cell populations, and the expression and transcriptional regulation
of ICs and their ligands within the CRC TME. Investigating the functional activity of the
different lymphoid cell populations and performing functional annotations for these genes
would add to the importance of these data, ultimately for uncovering means of resistance
to cancer immunotherapy.
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